Epidermal growth factor inhibitors in first-line for metastatic colorectal cancer with ras wild-type: a perspective based on pharmacological costs [0.03%]
基于药学成本的转移性野生型ras结直肠癌一线使用表皮生长因子受体抑制剂的观点分析
Jacopo Giuliani,Andrea Bonetti
Jacopo Giuliani
In light of the relevant expenses of pharmacological interventions it might be interesting to make a balance between the cost of the new drugs administered, such as EGFRIs (cetuximab and panitunumab) and the added value represented by the i...
Cost-effectiveness analysis of insulin degludec compared with insulin glargine u100 for the management of type 1 and type 2 diabetes mellitus - from the Spanish National Health System perspective [0.03%]
从西班牙国家卫生系统角度分析德谷胰岛素与甘精胰岛素u100治疗1型和2型糖尿病的性价比研究
Pedro Mezquita-Raya,Josep Darbà,Meritxell Ascanio et al.
Pedro Mezquita-Raya et al.
Background: The objective of this study was to assess the cost-effectiveness of insulin degludec versus insulin glargine, from the Spanish NHS in three groups of patients. ...
The ESMO-Magnitude of Clinical Benefit Scale for novel oncology drugs: correspondence with three years of reimbursement decisions in Israel [0.03%]
欧洲医学肿瘤学会的临床效益规模在以色列抗癌药物报销决策中的应用分析
Ariel Hammerman,Sari Greenberg-Dotan,Ilan Feldhamer et al.
Ariel Hammerman et al.
Background: The European Society for Medical Oncology published in 2015 its Magnitude of Clinical Benefit Scale (ESMO-MCBS) for cancer medicines. Our objective was to evaluate the association between Israel's national rei...
A systematic review of the health economic consequences of quadrivalent influenza vaccination [0.03%]
四价流感疫苗卫生经济学影响的系统评价研究进展
Pieter T de Boer,Britt M van Maanen,Oliver Damm et al.
Pieter T de Boer et al.
Quadrivalent influenza vaccines (QIVs) contain antigens derived from an additional influenza type B virus as compared with currently used trivalent influenza vaccines (TIVs). This should overcome a potential reduced vaccine protection due t...
David D Kim,Colby L Wilkinson,Elle F Pope et al.
David D Kim et al.
Background: Debates persist on the appropriate time horizon from a payer's perspective and how the time horizon in cost-effectiveness analysis (CEA) influences the value assessment. ...
Impact of price deregulation policy on the affordability of essential medicines for women's health: a panel data analysis [0.03%]
价格放开政策对女性健康基本药物可负担性的影响：基于面板数据的分析
Junjie Liu,Liming Wang,Chenxi Liu et al.
Junjie Liu et al.
Background: A new policy which required deregulation on prices of off-patent medicines for women's health during procurement was introduced in China in September 2015. The current study examines this policy's impact on th...
Cost-utility of biological treatment sequences for luminal Crohn's disease in Europe [0.03%]
欧洲乳糜泻克罗恩病生物制剂序贯治疗的成本效用分析
Fanni Rencz,László Gulácsi,Márta Péntek et al.
Fanni Rencz et al.
Background: This study aims to compare the cost-effectiveness of treatment sequences with available biologics, including adalimumab (ADA), biosimilar infliximab (bsIFX), originator infliximab (IFX) and vedolizumab (VEDO) ...
Cost-effectiveness of vildagliptin for people with type 2 diabetes mellitus in Brazil; findings and implications [0.03%]
西格列汀治疗巴西2型糖尿病患者的经济效果及意义分析
Gustavo Laine Araujo De Oliveira,Augusto Afonso Guerra Júnior,Brian Godman et al.
Gustavo Laine Araujo De Oliveira et al.
Vildagliptin is an inhibitor of the enzyme dipeptidyl peptidase 4, indicated for the treatment of type 2 diabetes mellitus, combined or not with metformin. This study aims to evaluate the cost-effectiveness of vildagliptin in the Brazilian ...
Analysis of the implementation of a personalized care model in diabetes mellitus as an example of chronic disease with information and communication technology support [0.03%]
基于信息和通信技术支援的糖尿病个性化护理模式实证研究——以慢性病为例
N López-Martínez,J L Segú,J Vázquez-Castro et al.
N López-Martínez et al.
Diabetes mellitus affects 13.8% of the adult population in Spain, representing some 8.2% of total Spanish health spending, which may be reduced by optimizing treatment and disease monitoring. Areas covered: This perspective article aims to ...